Post hoc analysis of the phase 3 QUEST trial (1584 patients with uncontrolled type 2 asthma): dupilumab plus medium-dose ICS cut severe exacerbations by 70% vs placebo plus high-dose ICS, with FEV1 +0.22 L and higher odds of asthma control (OR 2.26).
Secondary analysisn = 1,584
Busse et al. Improved asthma outcomes with dupilumab plus medium-dose inhaled corticosteroids vs placebo plus high-dose inhaled corticosteroids